Neurodegenerative Diseases
4
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
On Market (1)
Approved therapies currently available
U
PIMAVANSERINApproved
pimavanserin
Unknown Companyoral
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Acadia PharmaceuticalsPimavanserin
AlectorLatozinemab
SciNeuro PharmaceuticalsSNP318
Clinical Trials (3)
Total enrollment: 151 patients across 3 trials
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Start: Jan 2023Est. completion: Aug 202675 patients
Phase 4Recruiting
Continuation Study for Latozinemab
Start: Dec 2023Est. completion: Jan 2026
Phase 3Terminated
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
Start: Mar 2023Est. completion: Nov 202376 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 151 patients
3 companies competing in this space